T-cell receptors identified by a personalized antigen-agnostic screening approach target shared neoantigen KRAS Q61H

Adoptive cell therapy (ACT) with TCR-engineered T-cells represents a promising alternative to TIL- or CAR-T therapies for patients with advanced solid cancers. Currently, selection of therapeutic TCRs critically depends on knowing the target antigens, a condition excluding most patients from treatme...

Full description

Saved in:

Bibliographic Details
Main Authors:	Volker Lennerz, Christoph Doppler, Martina Fatho, Anja Dröge, Sigrid Schaper, Kristin Gennermann, Nadine Genzel, Stephanie Plassmann, David Weismann, Samuel W. Lukowski, Dominik Bents, Christina Beushausen, Karen Kriese, Hermann Herbst, Volkhard Seitz, Rudolf Hammer, Paul J. Adam, Stephan Eggeling, Catherine Wölfel, Thomas Wölfel, Steffen Hennig
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-03-01
Series:	Frontiers in Immunology
Subjects:	T-cell receptor (TCR) TCR-T cell tumor-specific antigen neoantigen KRAS Q61H oncogenic driver gene
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1509855/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

T-cell receptors identified by a personalized antigen-agnostic screening approach target shared neoantigen KRAS Q61H

Similar Items